skip to main content

Rituximab – recurrent FSGS post-transplant — RACP Paediatrics MCQ

Instant feedback + full explanation. One question, done properly.

HardNephrologyRituximab – recurrent FSGS post-transplantRACP Paediatrics

A 12-year-old kidney transplant recipient with frequently relapsing nephrotic syndrome recurrence in the graft has failed standard immunosuppression optimisation. What additional agent targeting B-cells may be considered?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Rituximab

Rituximab (anti-CD20 monoclonal antibody) is used in transplant nephrology for: recurrent FSGS in the graft, antibody-mediated rejection, and post-transplant lymphoproliferative disorder (PTLD). For recurrent nephrotic syndrome post-transplant, rituximab combined with plasmapheresis may achieve remission.

Reference: RCH Melbourne – 2023 – Renal Transplant CPG; RACP Paediatric Curriculum – Nephrology